Retour aux projets

14785.1 PFLS-LS

14785.1 PFLS-LS

Résumé

Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders

Textes supplémentaires

Abstract

The objective of this project is the characterization and optimization of a new class of drug candidates based on allosteric modulation for neurodegenerative and psychiatric diseases. Specifically, allosteric modulators targeting Group III of metabotropic glutamate receptors will be assessed in animal models replicating human Parkinson‟s disease (mGluR4), whereas electrophysiological studies will be carried out on allosteric modulators targeting mGluR4 and mGluR7, in order to investigate their role in modulating synaptic transmission and further characterize their potential therapeutic application in neurodegenerative diseases and anxiolytic disorders. Project results will contribute in the selection of the best candidate compounds for clinical development.

Participants

Graham Dixon

Wirtschaftspartner

graham.dixon@addextherapeutics.com

Addex Pharmaceuticals SA Graham Dixon Chemin des Aulx 12 1228 Plan-les-Ouates GE CH

Ron Stoop

Kontaktperson

Ron.Stoop@unil.ch

CHUV Centre Hospitalier Universitaire Va Centre for Psychiatric Neuroscience Ron Stoop Hôpital de Cery / Route de Cery 1005 Lausanne VD CH

Détails du projet

Office de recherche
INNOSUISSE
Statut du projet
Abgeschlossen
Type de projet
Forschungsprojekt
Date de début
2013-05-31
Date de fin
2015-11-30
Coûts totaux approuvés
CHF 708030.00
Section
20 Förderbereich Life Sciences
Domaine politique NABS
Industrielle Produktivität und Technologie

Disciplines de recherche

  • T490 Biotechnology 100.0%